본문으로 건너뛰기
← 뒤로

Hepatocellular carcinoma: Clinical trials to watch.

Med (New York, N.Y.) 2026 Vol.7(3) p. 101038

Hsiehchen D, Singal AG

📝 환자 설명용 한 줄

Ongoing trials for hepatocellular carcinoma (HCC) screening and treatment have the potential to transform management.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Hsiehchen D, Singal AG (2026). Hepatocellular carcinoma: Clinical trials to watch.. Med (New York, N.Y.), 7(3), 101038. https://doi.org/10.1016/j.medj.2026.101038
MLA Hsiehchen D, et al.. "Hepatocellular carcinoma: Clinical trials to watch.." Med (New York, N.Y.), vol. 7, no. 3, 2026, pp. 101038.
PMID 41831431

Abstract

Ongoing trials for hepatocellular carcinoma (HCC) screening and treatment have the potential to transform management. Screening trials are comparing novel imaging and blood-based strategies versus abdominal ultrasound for early HCC detection. Immune checkpoint inhibitors have transformed the therapeutic landscape, with trials evaluating potential benefit in early-stage or intermediate-stage HCC as well as new regimens to improve survival for advanced-stage HCC.

MeSH Terms

Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Immune Checkpoint Inhibitors; Clinical Trials as Topic; Early Detection of Cancer; Neoplasm Staging